Safety and Feasibility of Reversible Induction Strategy

Safety and Feasibility of Reversible Induction Strategy Supported by HFNC Combined With Specific Anesthetic

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04434963

Enrollment

Registered

2020-06-17

Start date

2021-02-01

Completion date

2021-12-01

Last updated

2021-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Cancer, Gastric Cancer, Patients With Uncertain Difficult Airway, Prostatic Cancer

Keywords

THRIVE, Uncertain difficult airway, Reversible induction strategy

Brief summary

This study would explore the safety and feasibility of a reversible induction strategy for uncertain difficult airway. This reversible induction strategy would include high flow nasal canular oxygenation support, short-term effect anesthetic including Propofol and Remifentanil for sedation and analgesia and Sugammadex would be used for reverse the muscle relaxant.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* \>18 years old,\<65 years old * Signed informed consent * Undergoing selective operation （ time of operation is over two hours） * ASA classification I-II * Mallampati classification 3-4 * suspicious difficult airway, but the anesthetists decide to try to rapid induction

Exclusion criteria

* Patients with several dysfunctions of liver, kidney or heart) * Patients with a full stomach or have other risk factors of reflux aspiration * Any medicine was taken before surgery, which might enhance or mitigate the effects of muscle relaxant * Infection of the mouth or nose * Allergy history of any medicine which would be used in this study * Pregnant and lactating women * Patients with neuromuscular disease

Design outcomes

Primary

Measure	Time frame
Successful rate of reversion	From the beginning of induction to 15min later

Secondary

Measure	Time frame
TOFr 0.9 reversion time	From the beginning of induction to 15min later
BIS 80 reversion time	From the beginning of induction to 15min later
Tidal volume 6-8ml tidal volume 6-8ml/kg reversion time	From the beginning of induction to 15min later
consciousness reversion time	From the beginning of induction to 15min later

Countries

China

Contacts

Primary Contactdiansan su

diansansu@yahoo.com+862168383702

Backup ContactXiaoying Chi, M.S.

chixiaoying@renji.com+86 18201706040

Outcome results